Paper39247341
Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: A review.
Habibizadeh M and 4 others. Heliyon, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: A review. Papers, record 39247341. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39247341
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28290155 | Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment. | Top Curr Chem (Cham) | 2017 | https://conductscience.org/library/papers/28290155 | PubMed |
| 2 | 29859281 | The proton sponge hypothesis: Fable or fact? | Eur J Pharm Biopharm | 2018 | https://conductscience.org/library/papers/29859281 | PubMed |
| 3 | 32112851 | Autophagy inhibition changes the disposition of non-viral gene carriers during blood-brain barrier penetration and enhances TRAIL-induced apoptosis in brain metastatic tumor. | J Control Release | 2020 | https://conductscience.org/library/papers/32112851 | PubMed |
| 4 | 28140697 | PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma. | J Drug Target | 2017 | https://conductscience.org/library/papers/28140697 | PubMed |
| 5 | 22648524 | Branched and linear poly(ethylene imine)-based conjugates: synthetic modification, characterization, and application. | Chem Soc Rev | 2012 | https://conductscience.org/library/papers/22648524 | PubMed |
| 6 | 31333662 | Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31333662 | PubMed |
| 7 | 33942822 | Magnetic nanocomplexes for gene delivery applications. | J Mater Chem B | 2021 | https://conductscience.org/library/papers/33942822 | PubMed |
| 8 | 12660816 | Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. | Oncogene | 2003 | https://conductscience.org/library/papers/12660816 | PubMed |
| 9 | 16373718 | Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. | Mol Cancer Ther | 2005 | https://conductscience.org/library/papers/16373718 | PubMed |
| 10 | 31550511 | Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment. | Int J Pharm | 2020 | https://conductscience.org/library/papers/31550511 | PubMed |
| 11 | 37065863 | Nano-TRAIL: a promising path to cancer therapy. | Cancer Drug Resist | 2023 | https://conductscience.org/library/papers/37065863 | PubMed |
| 12 | 24076237 | TRAIL on trial: preclinical advances in cancer therapy. | Trends Mol Med | 2013 | https://conductscience.org/library/papers/24076237 | PubMed |
| 13 | 32718904 | TRAIL of Hope Meeting Resistance in Cancer. | Trends Cancer | 2020 | https://conductscience.org/library/papers/32718904 | PubMed |
| 14 | 29172759 | Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. | Drug Deliv | 2017 | https://conductscience.org/library/papers/29172759 | PubMed |
| 15 | 11479629 | Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. | Nat Med | 2001 | https://conductscience.org/library/papers/11479629 | PubMed |
| 16 | 25555748 | Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. | Drug Discov Today | 2015 | https://conductscience.org/library/papers/25555748 | PubMed |
| 17 | 22407575 | Resistance to TRAIL and how to surmount it. | Immunol Res | 2012 | https://conductscience.org/library/papers/22407575 | PubMed |
| 18 | 36594589 | Fluorescent Self-Reporting Lipid Nanoparticles for Nitric Oxide/Gene Co-Delivery and Combination Therapy. | Mol Pharm | 2023 | https://conductscience.org/library/papers/36594589 | PubMed |
| 19 | 12215894 | Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. | Gene Ther | 2002 | https://conductscience.org/library/papers/12215894 | PubMed |
| 20 | 21306770 | Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. | Biomaterials | 2011 | https://conductscience.org/library/papers/21306770 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42835823 | The Nanoparticle Delivery Gap in Immune Cell Engineering: From Uptake to Endosomal Escape. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42835823 | PubMed |
| 42587825 | Graphene Oxide Modulates ROS Production and Apoptotic Responses to Bortezomib in Human Glioblastoma Cells: An In Vitro Study. | Cells | 2026 | https://conductscience.org/library/papers/42587825 | PubMed |
| 40530018 | Current trends in theranostic applications of extracellular vesicles in cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/40530018 | PubMed |
| 40390226 | Porphyrin-based MOFs for Gene Delivery in Cancer Therapy: Recent Advances and Progress. | Curr Pharm Des | 2026 | https://conductscience.org/library/papers/40390226 | PubMed |
| 40124336 | Tailored virus-mimicking nanoparticles mediate high transfection of pTRAIL for bystander effects in oncotherapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40124336 | PubMed |
| 40084090 | Basic and applied research progress of TRAIL in hematologic malignancies. | Blood Sci | 2025 | https://conductscience.org/library/papers/40084090 | PubMed |
| 40060291 | Targeting the interplay between human papillomavirus oncoproteins and hedgehog signaling: assessment of chemopreventive potential of carvacrol in cervical cancer. | 3 Biotech | 2025 | https://conductscience.org/library/papers/40060291 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| TNFRSF10A | 8797 | PubTator's text mining | https://conductscience.org/library/genes/8797 | NCBI Gene |
| TNFRSF10B | 8795 | PubTator's text mining | https://conductscience.org/library/genes/8795 | NCBI Gene |
| TNFSF10 | 8743 | PubTator's text mining | https://conductscience.org/library/genes/8743 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39247341
GET https://conductscience.org/api/papers/v1/39247341/references?page=2